{
    "root": "1468f2ff-4355-402a-8c46-0b9272ae633e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Pioglitazone Hydrochloride and Metformin Hydrochloride"
    },
    "value": "20250227",
    "ingredients": [
        {
            "name": "PIOGLITAZONE HYDROCHLORIDE",
            "code": "JQT35NPK6C"
        },
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE CALCIUM",
            "code": "UTY7PDF93L"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "pioglitazone metformin hydrochloride tablets indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus . limitations pioglitazone metformin hydrochloride tablets recommended treat type 1 diabetes mellitus diabetic ketoacidosis .",
    "contraindications": "obtain liver tests initiation . abnormal , caution treating pioglitazone metformin hydrochloride , investigate probable cause , treat ( possible ) , follow appropriately . ( 2.1 ) take orally meals reduce gastrointestinal metformin ( 2.10 ) individualize starting dose based patient \u2019 current regimen titrate gradually , needed assessing therapeutic response tolerability . maximum recommended total daily pioglitazone 45 mg metformin 2,550 mg. ( 2.2 ) recommended starting patients nyha class class ii congestive heart failure 15 mg pioglitazone 500 mg metformin hydrochloride 15 mg pioglitazone 850 mg metformin hydrochloride orally daily . ( 2.4 ) prior initiation , assess renal function estimated glomerular filtration rate ( egfr ) . ( 2.2 ) contraindicated patients egfr 30 ml/min initiation recommended patients egfr 30 45 ml/min assess risk/benefit continuing pioglitazone metformin hydrochloride egfr falls 45 ml/min discontinue egfr falls 30 ml/min monitor patients events related fluid retention initiation dose increases . ( 2.4 ) pioglitazone metformin hydrochloride may need discontinued time , prior , iodinated contrast imaging procedures . ( 2.6 )",
    "warningsAndPrecautions": "pioglitazone metformin hydrochloride tablets usp , 15 mg/500 mg white off-white , oblong , biconvex film-coated tablets , debossed \u2018 h \u2019 one side \u2018 92 \u2019 side . bottles 60 ndc 65862-525-60 bottles 180 ndc 65862-525-18 pioglitazone metformin hydrochloride tablets usp , 15 mg/850 mg white off-white , oblong , biconvex film-coated tablets , debossed \u2018 h \u2019 one side \u2018 93 \u2019 side . bottles 60 ndc 65862-526-60 bottles 180 ndc 65862-526-18 storage : store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ] keep container tightly closed , protect moisture humidity .",
    "adverseReactions": "pioglitazone metformin hydrochloride contraindicated patients : established nyha class iii iv heart failure time pioglitazone metformin hydrochloride initiation [ boxed warning ] . severe renal impairment ( egfr 30 ml/min ) [ ( 5.2 ) ] . history serious hypersensitivity pioglitazone , metformin hydrochloride , excipients pioglitazone metformin hydrochloride tablets . acute chronic metabolic acidosis , including diabetic ketoacidosis [ ( 5.2 ) ] .",
    "indications_original": "Pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. \n                  \n                  \n                     Limitations of Use\n                  \n                  Pioglitazone and metformin hydrochloride tablets are not recommended to treat type 1 diabetes mellitus or diabetic ketoacidosis.",
    "contraindications_original": "Obtain liver tests before initiation. If abnormal, use caution when treating with pioglitazone and metformin hydrochloride, investigate the probable cause, treat (if possible), and follow appropriately. ( 2.1 ) Take orally with meals to reduce gastrointestinal adverse reactions with metformin (2.10) Individualize the starting dose based on the patient\u2019s current regimen and titrate the dosage gradually, as needed after assessing therapeutic response and tolerability. The maximum recommended total daily dosage is pioglitazone 45 mg and metformin 2,550 mg. ( 2.2 ) Recommended starting dosage in patients with NYHA Class I or Class II congestive heart failure is 15 mg of pioglitazone and 500 mg of metformin hydrochloride or 15 mg of pioglitazone and 850 mg of metformin hydrochloride orally once daily. ( 2.4 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR). ( 2.2 ) Contraindicated in patients with eGFR below 30 mL/min Initiation is not recommended in patients with eGFR between 30 to 45 mL/min Assess risk/benefit of continuing pioglitazone and metformin hydrochloride if eGFR falls below 45 mL/min Discontinue if eGFR falls below 30 mL/min Monitor patients for adverse events related to fluid retention after initiation and dose increases. ( 2.4 ) Pioglitazone and metformin hydrochloride may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures. ( 2.6 )",
    "warningsAndPrecautions_original": "Pioglitazone and Metformin Hydrochloride Tablets USP, 15 mg/500 mg are white to off-white, oblong, biconvex film-coated tablets, debossed with \u2018H\u2019 on one side and \u201892\u2019 on other side.\n                     \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 60\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-525-60 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 180\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-525-18\u00a0\n                     \n                     Pioglitazone and Metformin Hydrochloride Tablets USP, 15 mg/850 mg are white to off-white, oblong, biconvex film-coated tablets, debossed with \u2018H\u2019 on one side and \u201893\u2019 on other side.\n                     \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 60\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-526-60 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 180\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-526-18\u00a0\n                     \n                     Storage: \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Keep container tightly closed, and protect from moisture and humidity.",
    "adverseReactions_original": "Pioglitazone and metformin hydrochloride are contraindicated in patients with:\n                  \n                     Established NYHA Class III or IV heart failure at the time of pioglitazone and metformin hydrochloride initiation [see Boxed Warning].\n                     Severe renal impairment (eGFR below 30 mL/min) [see Warnings and Precautions (5.2)].\n                     A history of serious hypersensitivity to pioglitazone, metformin hydrochloride, or any of the excipients in pioglitazone and metformin hydrochloride tablets. \n                     Acute or chronic metabolic acidosis, including diabetic ketoacidosis [see Warnings and Precautions (5.2)]."
}